Ipilimumab in the Treatment of Prostate Cancer

References

• Siegel R , NaishadhamD, JemalA. Cancer statistics, 2013. CA Cancer J. Clin.63(1), 11–30 (2013).
   PubMed Web of Science ®Google Scholar
• Crawford ED , EisenbergerMA, McLeodDGet al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med.321(7), 419–424 (1989).
   PubMed Web of Science ®Google Scholar
• Tannock IF , de WitR, BerryWRet al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak DP , TangenCM, HussainMHet al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , HiganoCS, ShoreNDet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Vergati M , IntriviciC, HuenNY, SchlomJ, TsangKY. Strategies for cancer vaccine development. J. Biomed. Biotechnol.2010, 596432 (2010).
   PubMedGoogle Scholar
• Sonpavde G , SlawinKM, SpencerDM, LevittJM. Emerging vaccine therapy approaches for prostate cancer. Rev. Urol.12(1), 25–34 (2010).
   PubMedGoogle Scholar
• Kantoff PW , SchuetzTJ, BlumensteinBAet al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol.28(7), 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Drake CG . Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol.10(8), 580–593 (2010).
   PubMed Web of Science ®Google Scholar
• Tagawa ST , BeltranH, VallabhajosulaSet al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer116(4 Suppl.), 1075–1083 (2010).
   PubMed Web of Science ®Google Scholar
• Morris MJ , DivgiCR, Pandit-TaskarNet al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin. Cancer Res.11(20), 7454–7461 (2005).
   PubMed Web of Science ®Google Scholar
• Galsky MD , EisenbergerM, Moore-CooperSet al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol.26(13), 2147–2154 (2008).
   PubMed Web of Science ®Google Scholar
• Milowsky MI , NanusDM, KostakogluL, VallabhajosulaS, GoldsmithSJ, BanderNH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol.22(13), 2522–2531 (2004).
   PubMed Web of Science ®Google Scholar
• Bander NH , MilowskyMI, NanusDM, KostakogluL, VallabhajosulaS, GoldsmithSJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol.23(21), 4591–4601 (2005).
   PubMed Web of Science ®Google Scholar
• Tagawa ST , MilowskyMI, MorrisMet al. Phase II trial of 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). J. Clin. Oncol.26(15 Suppl.), 5140 (2008).
   PubMed Web of Science ®Google Scholar
• Tagawa ST , VallabhajosulaS, OsborneJet al. Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). J. Clin. Oncol.28(15 Suppl.), 4667 (2010).
   PubMed Web of Science ®Google Scholar
• Fong L , SmallEJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol.26(32), 5275–5283 (2008).
   PubMed Web of Science ®Google Scholar
• Smith-Garvin JE , KoretzkyGA, JordanMS. T cell activation. Annu. Rev. Immunol.27, 591–619 (2009).
   PubMed Web of Science ®Google Scholar
• Kwek SS , DaoV, RoyRet al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J. Immunol.189(7), 3759–3766 (2012).
   PubMed Web of Science ®Google Scholar
• Oosterwegel MA , GreenwaldRJ, MandelbrotDA, LorsbachRB, SharpeAH. CTLA-4 and T cell activation. Curr. Opin. Immunol.11(3), 294–300 (1999).
   PubMed Web of Science ®Google Scholar
• Small EJ , TchekmedyianNS, RiniBI, FongL, LowyI, AllisonJP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res.13(6), 1810–1815 (2007).
   PubMed Web of Science ®Google Scholar
• Cooperberg MR . The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE), a national disease registry. J. Urol.171, 1393–1401 (2004).
   PubMed Web of Science ®Google Scholar
• Krummel MF , AllisonJP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med.182(2), 459–465 (1995).
   PubMed Web of Science ®Google Scholar
• Tivol EA , BorrielloF, SchweitzerAN, LynchWP, BluestoneJA, SharpeAH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity3(5), 541–547 (1995).
   PubMed Web of Science ®Google Scholar
• Waterhouse P , PenningerJM, TimmsEet al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science270(5238), 985–988 (1995).
   PubMed Web of Science ®Google Scholar
• Leach DR , KrummelMF, AllisonJP. Enhancement of antitumor immunity by CTLA-4 blockade. Science271(5256), 1734–1736 (1996).
   PubMed Web of Science ®Google Scholar
• Yang YF , ZouJP, MuJet al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res.57(18), 4036–4041 (1997).
   PubMed Web of Science ®Google Scholar
• Hurwitz AA , YuTF, LeachDR, AllisonJP. CTLA-4 blockade synergizes with tumor-derived granulocyte–macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA95(17), 10067–10071 (1998).
   PubMed Web of Science ®Google Scholar
• Grosso JF , Jure-KunkelMN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun.13, 5 (2013).
   PubMedGoogle Scholar
• Kwon ED , HurwitzAA, FosterBAet al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl Acad. Sci. USA94(15), 8099–8103 (1997).
   PubMed Web of Science ®Google Scholar
• Hurwitz AA , FosterBA, KwonEDet al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res.60(9), 2444–2448 (2000).
   PubMed Web of Science ®Google Scholar
• Madan RA , MohebtashM, ArlenPMet al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a Phase 1 dose-escalation trial. Lancet Oncol.13(5), 501–508 (2012).
   PubMed Web of Science ®Google Scholar
• van den Eertwegh AJ , VersluisJ, van den BergHPet al. Combined immunotherapy with granulocyte–macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a Phase 1 dose-escalation trial. Lancet Oncol.13(5), 509–517 (2012).
   PubMed Web of Science ®Google Scholar
• Slovin SF , HiganoCS, HamidOet al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol.24(7), 1813–1821 (2013).
   PubMed Web of Science ®Google Scholar
• Chakraborty M , AbramsSI, CamphausenKet al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol.170(12), 6338–6347 (2003).
   PubMed Web of Science ®Google Scholar
• Chakraborty M , AbramsSI, ColemanCN, CamphausenK, SchlomJ, HodgeJW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res.64(12), 4328–4337 (2004).
   PubMed Web of Science ®Google Scholar
• Apetoh L , GhiringhelliF, TesniereAet al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med.13(9), 1050–1059 (2007).
   PubMed Web of Science ®Google Scholar
• Kwon ED , DrakeCG, ScherHIet al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Phase 3 trial. Lancet Oncol.15(7), 700–712 (2014).
   PubMed Web of Science ®Google Scholar
• Weber JS , KahlerKC, HauschildA. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol.30(21), 2691–2697 (2012).
   PubMed Web of Science ®Google Scholar
• Hodi FS , O’DaySJ, McDermottDFet al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Schellhammer PF , ChodakG, WhitmoreJB, SimsR, FrohlichMW, KantoffPW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology81(6), 1297–1302 (2013).
   PubMed Web of Science ®Google Scholar